Management of "refractory" skin disease in patients with lupus erythematosus
Related Experiment Video
Updated: Aug 14, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
1Division of Dermatology, School of Medicine, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA. jefca@aol.com
Abstract:
Skin disease in patients with lupus erythematosus can be subdivided into two broad categories-those lesions that, when biopsied, demonstrate an interface dermatitis and those that do not demonstrate an interface dermatitis. The skin lesions that are represented by the interface dermatitis include discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus. Many patients with these cutaneous lesions can be managed with "standard" therapies, including sunscreens, protective clothing and behavioral alteration, and topical corticosteroids with or without an oral antimalarial agent. These standard therapies are often not used appropriately, resulting in a situation in which the patient is felt to have refractory disease. This chapter discusses these therapies and defines what is meant by refractory disease and how the author approaches these patients.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Rheumatic Heart Disease IV: Nursing Management
Peripheral Artery Disease IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Acne Infection

